Aardvark Therapeutics
AARD
27 hedge funds and large institutions have $65.1M invested in Aardvark Therapeutics in 2025 Q1 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
40.63% more ownership
Funds ownership: 0% → 40.63% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
+$44M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$9.08M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.98M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$5.61M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $16.7K | +$24.9K | +2,218 | New |
|
|
PAS
27
Point72 Asia (Singapore)
Singapore
| $9.64K | +$14.4K | +1,284 | New |
|
AARD Hedge Fund Activity: Q1 2025 in Review
27 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q1 2025, worth a combined $65.1M.
Buyers outnumbered sellers: 27 funds opened new AARD positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Decheng Capital, opening a new position worth an estimated $44M.
- 27 institutional investors held Aardvark Therapeutics (AARD) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $65.1M of Aardvark Therapeutics stock for Q1 2025.
- 27 funds opened new Aardvark Therapeutics positions in Q1 2025 and 0 closed out, a net change of +27 holders.
- The largest Aardvark Therapeutics buyer in Q1 2025 was Decheng Capital, an estimated $44M added.
Based on aggregated 13F filings for Q1 2025.